BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 9255199)

  • 41. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus.
    Sindhi R; Webber S; Venkataramanan R; McGhee W; Phillips S; Smith A; Baird C; Iurlano K; Mazariegos G; Cooperstone B; Holt DW; Zeevi A; Fung JJ; Reyes J
    Transplantation; 2001 Sep; 72(5):851-5. PubMed ID: 11571449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Uribe M; Hunter B; Alba A; Calabrán L; Flores L; Soto P; Herzog C
    Transplant Proc; 2009; 41(6):2679-81. PubMed ID: 19716000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
    Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
    Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of lymphoproliferative disease after liver transplantation.
    Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.
    Berenguer M; Prieto M; Córdoba J; Rayón JM; Carrasco D; Olaso V; San-Juan F; Gobernado M; Mir J; Berenguer J
    J Hepatol; 1998 May; 28(5):756-63. PubMed ID: 9625309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
    Deng Z; Jiang L; Zhou T; Shen C; Chen Q; Xia Q
    Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):579-82. PubMed ID: 25224233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
    Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sirolimus in pediatric liver transplantation: a single-center experience.
    Gibelli NE; Tannuri U; Pinho-Apezzato ML; Tannuri AC; Maksoud-Filho JG; Andrade WC; Velhote MC; Santos MM; Ayoub AA; Marques da Silva M
    Transplant Proc; 2009 Apr; 41(3):901-3. PubMed ID: 19376384
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
    Kim JM; Lee SK; Kim SJ; Joh JW; Kwon CH; Choe YH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS
    Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
    Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Cacciarelli TV; Reyes J; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Green M
    Pediatr Transplant; 2001 Oct; 5(5):359-64. PubMed ID: 11560756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder.
    Badley AD; Portela DF; Patel R; Kyle RA; Habermann TM; Strickler JG; Ilstrup DM; Wiesner RH; de Groen P; Walker RC; Paya CV
    Liver Transpl Surg; 1996 Sep; 2(5):375-82. PubMed ID: 9346679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.